Temporal characteristics of treatment-emergent adverse events and dose modifications with tivozanib and sorafenib in the phase 3 TIVO-3 study of relapsed or refractory mRCC.
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: City Of Hope National Medical Center, City of Hope, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Institut Gustave Roussy, Fondation Gustave Roussy, Texas A&M University, University of Bari Aldo Moro, Fondazione IRCCS Istituto Nazionale dei Tumori, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, AVEO Oncology (United States), Vanderbilt University, Vanderbilt-Ingram Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3170218840